Corporate Banner
Satellite Banner
Technology Networks Header
Saturday, October 25, 2014
Technology Networks
 
Register | Sign in
Safe Weighing and Handling of Potent Dru...
Companion Diagnostics Development at the...Webinar: Drug-drug combinations made sim...ETP Nanomedicine and NANOMED2020: Toward...

Featured Products
Featured Product - Biomarker Discovery & Development
Biomarker Discovery & Development

Webcasts
Webcasts - ETP Nanomedicine and NANOMED2020: Towards a New Nanomedicine HorizonETP Nanomedicine and NANOMED2020: Towards a New Nanomedicine Horizon
Olivier Fontaine, Nanobiotix, speaking at Nanomedicine 2014.
Webcasts - TagLite® 2 cell assay - the next dimension to discovering new antibody drugsTagLite® 2 cell assay - the next dimension to discovering new antibody drugs
Sandra Grau-Richards, Senior Scientist/Team Leader Roche-Glycart

Market Reports
Immunoassay Auto Trends 2014
HTStec

This report comprehensively documents current practices and preferences in immunoassays and to understand future user requirements, particularly with respect to immunoassay automation.
Gene Expression Analysis Market by Technology, Consumables, Services & Applications - Global Forecast to 2018
MarketsandMarkets

Over the years, the gene expression analysis market, comprising of instruments, consumables, and services, has witnessed various technological advancements. These advancements have led to a growth in the number of gene expression applications.
Epigenetic Modification Screening Trends 2014
HTStec

This market report summarizes the results of HTStec’s 3nd industry-wide global web-based benchmarking survey on epigenetic modification screening carried out in May 2014.
Multi-Mode Microplate Reader Trends 2013
HTStec

This market report summarizes the results of HTStec’s 4th industry-wide global web-based benchmarking survey on multi-mode microplate readers carried out in September 2013.
GPCR Screening & Profiling Trends 2013
HTSTec

This market report summarizes the results of HTStec’s 5th industry-wide global web-based benchmarking survey on GPCR screening and profiling carried out in August 2013.
China Pharmaceutical Market Outlook
Global Data

The report details the macroeconomic environment of China, providing a background of the financial and demographic situations in the country, as well as identifying key demographics. It covers the pharmaceutical market broken down by market segment, and the popularity of biosimilars and biologics, identifying where the strongest market potentials lie.
Pathways to Efficient Drug Development - Advances in Modeling and Simulation Outcomes to Fuel Pipeline Productivity
GBI Research

The report examines the reasons why the pharmaceutical industry is looking for improvements in efficiency whilst acknowledging that pharmaceutical R&D remains a long and risky process. It looks in detail at precompetitive research and evaluates how the industry is pulling together to research solutions to problems that are common to all companies.
Drug Discovery and Development Market in Asia
Global Data

The report provides key data, information and analysis of the major trends and issues affecting the drug discovery and development market in seven major countries in Asia, namely China, India, Russia, Japan, Singapore, Taiwan and South Korea.
Biopharmaceutical Manufacturing in India, China and South Korea
GBI Research

The report provides an analysis of biopharmaceuticals approved in 2010 and 2011, operating dynamics in the biopharmaceutical industry, the current scenario in biopharmaceutical manufacturing, key stakeholders, the current market size (2011) of biopharmaceuticals, and forecasts to 2016 for India, China, South Korea and the global market.
Outsourced Ion Channel Testing Trends 2013
HTStec

HTStec's Outsourced Ion Channel Testing Trends 2013 report was published on 3 May 2013. This 58 page market report summarizes the results of HTStec's industry-wide global web-based benchmarking survey on outsourced ion channel testing carried out in April 2013.
Scientific News
NIH Begins Early Human Clinical Trial of VSV Ebola Vaccine
Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health’s Clinical Center in Bethesda, Maryland.
Adaptimmune Announces Interim Results from Pilot Trial of NY-ESO T Cells
Study reports encouraging response rate and safety profile.
Personalized Ovarian Cancer Vaccines
UConn Researchers have found a new way to identify protein mutations in cancer cells.
Study Finds Potential New Target to Treat Asthma Attacks Brought on by Colds
Results suggest that IL-25 could be a target for possible treatments to prevent asthma attacks.
Novel Drug Targeting Leukemia Cells Enters Clinical Trial
Phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for CLL patients.
Animal Testing can Mislead Drug Discovery and Development
Several blockbuster drugs would not be on the market, if scientists had relied solely on drug-uptake in animal trials, according to new research.
Leukemia Subtype Becomes More Common With Age
Genomic Analysis of 1,725 patients reveals the prevalence of Ph-like ALL increases with age.
Clinical Trial to Test Safety of Stem Cell-Derived Therapy for Type 1 Diabetes
UC San Diego is initial site for first-in-human testing of implanted cell therapy.
NIH to Launch Human Safety Study of Ebola Vaccine Candidate
Trial is First in Series of Accelerated Safety Studies of Ebola Vaccines.
NIH Announces the Launch of 3 Integrated Precision Medicine Trials
ALCHEMIST is for patients with certain types of early-stage lung cancer.
Business News
Crown Bioscience Announces U.S. Expansion with New Translational Oncology Center
New service center will allow the expansion of new immunotherapy experimental platforms to advance translational medical research and the treatment of cancers.
Foundation Medicine and WuXi PharmaTech Collaborate
Collaboration to address needs of biopharmaceutical companies conducting clinical R&D in China.
FMI, WuXi PharmaTech Genomic Profiling Collaboration
Collaboration to address needs of biopharmaceutical companies conducting clinical R&D in China.
Athera Initiates Phase I Trial with its Fully Human Antibody PC-mAb
Current Phase I study is performed in Uppsala by CTC Clinical Trial Consultants AB.
13th Annual Partnerships in Clinical Trials Congress: Visionary insights into pioneering approaches and transparency in clinical trial partnerships
The latest developments in outsourcing and strategic partnerships in clinical trials will be put under the spotlight at the 13th Annual Partnerships in Clinical Trials (PCT) Congress in Barcelona on 5-6 November 2014.
Bart Filius Joins Galapagos as CFO
Bart will join the Executive Committee of Galapagos and be responsible for Finance, Investor Relations, IT, and Purchasing.
Vetter Announces Personnel Changes in its Development Service Division
Clinical manufacturing services continue to attract new business.
UM SOM and Malian Ministry of Health Begin Human Trials of Experimental Ebola Vaccine
First study of a promising Ebola vaccine undertaken in West Africa.
Promethera Receives Approval to Enroll Patients in the Imminent HEP002 Phase IIb/III Clinical Trial
HEP002 trial represents the world’s first Phase IIb/III trial with a stem cell-based medicinal product for the treatment of urea cycle disorders patients.
PCI Announces Opening of North American Clinical Facility
PCI opens North American storage and distribution facility for investigational medicinal products.

Events
4th Partnering with ACOs Summi
27 Oct 2014
4th Partnering with ACOs Summi ...
More information
Clinical Trial Billing Boot Ca
27 Oct 2014
Clinical Trial Billing Boot Ca ...
More information
2nd Annual Clinical Trials Sup
29 Oct 2014
2nd Annual Clinical Trials Sup ...
More information
Partnerships in Clinical Trial
05 Nov 2014
Partnerships in Clinical Trial ...
More information

ePosters
Enabling Epigenetics Studies from HTS to SAR : A Novel HTRF® Platform to Identify and Characterize Reader Domain Inhibitors
1Cisbio Bioassays Codolet, France | 2CRCM, CNRS UMR7258, INSERM U1068, AMU UM105, Institut Paoli-Calmettes, Marseille, France | 3AFMB, UMR7257, Univ. Aix Marseille-CNR

Discover a novel HTRF platform to identify and characterize the vast variety of epigenetic binding domain.

High Throughput Screening in the European Lead Factory
Pivot Park Screening Centre

This paper describes workflows that have been implemented at the screening centre of the European Lead Factory and presents screening statistics on the first 18 months of operation.
Novel Gpr39 Agonists: Correlation Of Binding Affinity Using Label-Free Back-Scattering Interferometry With Potency In Functional Assays
(1)Molecular Sensing, Inc., Nashville, Tennessee, USA, (2) AstraZeneca Discovery Sciences, Mölndal, Sweden, (3) AstraZeneca CVMD iMED, Mölndal, Sweden

We describe the application of back-scattering interferometry (BSI) to the characterization of small molecule ligand binding to human GPR39 (a GPCR targeted for type-2 diabetes therapy) overexpressed in crude membrane fractions in free solution, including how BSI-derived affinity and functional assay-derived potency correlate for compounds of varying scaffolds.
Mixtures Analysis of Complex Mixtures
Mestrelab Research

We describe an NMR method to quantify mixture components in wine, edible oils, etc. The method is fully customizable, and amenable to high throughput operation.
Novel Gpr39 Agonists: Correlation Of Binding Affinity Using Label-Free Back-Scattering Interferometry With Potency In Functional Assays
(1) Molecular Sensing, Inc., Nashville, Tennessee, USA, (2) AstraZeneca Discovery Sciences, Mölndal, Sweden, (3) AstraZeneca CVMD iMED, Mölndal, Sweden

We describe the application of back-scattering interferometry (BSI) to the characterization of small molecule ligand binding to human GPR39 (a GPCR targeted for type-2 diabetes therapy) overexpressed in crude membrane fractions in free solution, including how BSI-derived affinity and functional assay-derived potency correlate for compounds of varying scaffolds
GC-MS/MS ANALYSIS OF BENZODIAZEPINES USING ANALYTE PROTECTANTS
Thermo Fisher Scientific

Purpose: Assess the feasibility of using analyte protectants to improve the analysis of benzodiazepines.

Targeted cancer therapy based on blocking the expression of genes and small doses of oxaliplatin.
Centre for Medical Genetics Russian Academy of Medical Sciences, Koltsov Institute of Developmental Biology Russian Academy of Sciences

The major drawbacks of the prescribed chemotherapy, are still remain the significant side effects and drug - resistance. Even targeted chemotherapy by means of specific antibodies do not always help to solve these complications. Our purpose was to identify potential biological targets associated with the development of drug resistance and to develop a specific method of suppressing the viability of cancer cells exposed to low doses of standard chemotherapy.
Inverted Y Approach to Lumbosacral region - Analysis of 525 cases over 10 years
Amrita Institute of Medical Sciences

Traditional approach to lumosacral region utilizes midline incision, which often requires long incision to get sufficient exposure. We describe our experience with inverted Y approach to lumbosacral junction.
LC/MS/MS Quantitation of Eicosapentaenoic Acid in Rat Plasma
BASi

Eicosapentaenoic acid (EPA) is an omega-3 fatty acid, which has been documented to be important in biochemical and physiological processes including inflammatory response, blood clotting and the immune system. Eicosapentaenoic acid (EPA) appears in different forms in the blood including triglyceride, ethyl ester, or free acid. In this work we presented an LC/MS/MS method to quantitate the total eicosapentaenoic acid in rat plasma with a 96-well plate format.
Comparison of Dissociated Phoria Measuring Methods. Repeatability and Reliability
CBO

The aim of this study is to determine the reliability and compare reproducibility of different dissociated phoria measure tests.
Application Notes
Cellular Dopamine and Intracellular Calcium Signaling Using the Next Generation HTS Microplate Reader
BMG Labtech

Two cell-based signaling assays from Invitrogen, Fluo-4 Direct™ Calcium Assay and Tango™-bla U2OS GPCR Assay, were performed on the PHERAstar FS HTS instrument. The PHERAstar FS has several unique features that enhance the performance of these assays including direct optic bottom reading, high resolution cell layer scanning, injection at the point of measurement and dual emission detection.
Reaction Optimisation and Large Scale Synthesis
Syrris Ltd

A major benefit of flow chemistry is the ease and consistency of reaction scale up. In a flow reactor, high quality, reproducible mixing, excellent temperature control and superheating are maintained when increasing reaction volume.
Automated Turnkey Solubility and Permeability Assays
Molecular Devices

Millipore Corporation and Molecular Devices have partnered to provide platforms for solubility and permeability screening. The objective is to create automation-compatible 96- and 384-based systems with pre-validated methods, devices and analysis that can be run manually or in conjunction with standard laboratory automation.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv